Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

Winorbust Feb. 23 at 9:11 PM

$PPBT Coinsplitter must be getting paid by institutions that want to dump any remaining shares they have

0 · Reply

Winorbust Feb. 23 at 9:10 PM

$PPBT they need people like their buddy Smitty to help trick people into buying the shares they dump

0 · Reply

coinspitter Feb. 23 at 7:24 PM

$PPBT capitulation day, now it's up up up.

0 · Reply

Purplepayday Feb. 23 at 6:47 PM

$PPBT SEC NOTICE: Reverse stock split ! https://www.sec.gov/Archives/edgar/data/1729782/000101915526000066/purple424b3.htm

0 · Reply

roachfood Feb. 23 at 6:33 PM

$PPBT Last time I felt a massive weight being lifted from my chest was when my divorce papers were finalized. I think this may be close.

1 · Reply

MochiMeerkat Feb. 23 at 5:31 PM

’,@SqueezeSharkie operating on another level 🧠❄️ Cold vision, real substance. It doesn’t cost you anything but a click, make sure to follow him🔥 $TMDE $ANGH $ISPR $PPBT <>

0 · Reply

Purplepayday Feb. 23 at 5:21 PM

$PPBT You could try your luck in GOSS that just failed in PH 3 But with 80% Tutes that want to get out in plus i think that there’s coming a pump and dump in this week 👍

0 · Reply

Purplepayday Feb. 23 at 5:05 PM

$PPBT Oupps 👀 👇 🤷🏻‍♂️

2 · Reply

Winorbust Feb. 23 at 3:51 PM

$PPBT anyone know how bullish Smitty is today? On scale of 1-10 he’s probably an 11 lol

0 · Reply

Winorbust Feb. 23 at 3:51 PM

$PPBT under $0.50s, so if they are able to reverse split and not get delisted, then the 10-1 split will put this in the $4.00s which means under $1 again just as fast as last time, maybe even faster haha I really wonder if management is purposefully doing this so they can be delisted and then go private and then sell to big pharma and put all that money into their own pockets after getting retail traders to foot the Bill the whole time

0 · Reply

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Nov 14, 2025, 8:00 AM EST - 3 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 7:33 AM EDT - 4 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 20, 2025, 4:00 PM EDT - 4 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Sep 5, 2025, 4:00 PM EDT - 6 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Aug 27, 2025, 7:00 AM EDT - 6 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 7 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 8 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 9 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 10 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 10 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 1 year ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Mar 24, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Winorbust Feb. 23 at 9:11 PM

$PPBT Coinsplitter must be getting paid by institutions that want to dump any remaining shares they have

0 · Reply

Winorbust Feb. 23 at 9:10 PM

$PPBT they need people like their buddy Smitty to help trick people into buying the shares they dump

0 · Reply

coinspitter Feb. 23 at 7:24 PM

$PPBT capitulation day, now it's up up up.

0 · Reply

Purplepayday Feb. 23 at 6:47 PM

$PPBT SEC NOTICE: Reverse stock split ! https://www.sec.gov/Archives/edgar/data/1729782/000101915526000066/purple424b3.htm

0 · Reply

roachfood Feb. 23 at 6:33 PM

$PPBT Last time I felt a massive weight being lifted from my chest was when my divorce papers were finalized. I think this may be close.

1 · Reply

MochiMeerkat Feb. 23 at 5:31 PM

’,@SqueezeSharkie operating on another level 🧠❄️ Cold vision, real substance. It doesn’t cost you anything but a click, make sure to follow him🔥 $TMDE $ANGH $ISPR $PPBT <>

0 · Reply

Purplepayday Feb. 23 at 5:21 PM

$PPBT You could try your luck in GOSS that just failed in PH 3 But with 80% Tutes that want to get out in plus i think that there’s coming a pump and dump in this week 👍

0 · Reply

Purplepayday Feb. 23 at 5:05 PM

$PPBT Oupps 👀 👇 🤷🏻‍♂️

2 · Reply

Winorbust Feb. 23 at 3:51 PM

$PPBT anyone know how bullish Smitty is today? On scale of 1-10 he’s probably an 11 lol

0 · Reply

Winorbust Feb. 23 at 3:51 PM

0 · Reply

demo1one Feb. 23 at 3:08 PM

$PPBT

0 · Reply

Purplepayday Feb. 23 at 2:32 PM

$PPBT Will be exiting to see what the Market Cap is after the RS … if they are not delisted before the reverse stock split on 2nd of March 🤷🏻‍♂️

0 · Reply

Purplepayday Feb. 23 at 1:58 PM

$PPBT I don’t know if you have noticed that the share price here, for the past 5-6 years, have always been sitting (not at) below insider pricing .…. You haven’t noticed that @Smittysixty 👀🤡

0 · Reply

Purplepayday Feb. 23 at 10:16 AM

$PPBT It’s better to be invested in Israel on the TASE market,,,. Because there you can sell the same dual-listed shares for more than 25% higher price. It have been like that for more than a week now 🤔🤷🏻‍♂️

0 · Reply

Purplepayday Feb. 23 at 2:56 AM

$PPBT 🤡

0 · Reply

Smittysixty Feb. 22 at 11:53 PM

$PPBT I’ll be adding again this week as long as we’re sitting at or below insider pricing. That’s the only support level that actually matters. The fundamentals haven’t changed: • Pipeline strategy is perfectly aligned with the major oncology themes out of JPM • Institutions loaded heavily in Q4 — real filings, real money • Pipeline value jumped immediately with the FDA’s one‑pivotal‑study rule • 100 mg NT‑219 data still locked down tight • Three assets at critical inflection points: – one IND‑ready – one deepening clinical validation – one positioned for high‑demand combo strategies And the trolls pretend to sell 🤣 🤣. No better place to be positioned in this market than right here.

0 · Reply

Winorbust Feb. 22 at 5:35 PM

$PPBT would be impressive if we see this company delist and then we read that they end up selling to a big pharma. That would be golden corruption.

0 · Reply

Winorbust Feb. 22 at 5:11 AM

$PPBT I doubt they will accelerate delisting of us, cause the SEC is corrupt, and insiders want to keep robbing retail so they can keep their salaries going. However, what if this was managements plan? Get delisted so they could then sell the company and make a boat load split between themselves and no shareholders?

1 · Reply

Winorbust Feb. 22 at 5:08 AM

$PPBT Don’t forget to add on: Don’t listen to insanity from people like Smitty that either ignore or try to trick people into ignoring normal common sense and stuff that is right in front of their eyes. Such as his claim that all bearishness is fake. Just open your brokerage accounts and see how fake it is.

0 · Reply

Purplepayday Feb. 21 at 9:26 PM

$PPBT .. What do you think @Smittysixty ? Can you ask your A I if there’s anything Bullish about that ? 👇 👇

0 · Reply

Purplepayday Feb. 21 at 9:00 PM

$PPBT So, maybe it’s already T H E E N D

1 · Reply

allgoodstill Feb. 21 at 6:27 PM

$PPBT If there is one lesson that Bulls should have learned here other than NEVER INVEST IN ISREALI BIOS, is shorting is the best way to make money here.

0 · Reply

Market Cap	6.36M
Revenue (ttm)	0.00
Net Income (ttm)	-7.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	81,100
Avg Vol	340,382
Day's Range	N/A - N/A
Shares Out	12.85M
Stochastic %K	24%
Beta	0.66
Analysts	Sell
Price Target	$34.00